New targeted combination therapy with potential to eliminate relapsed chronic lymphocytic leukaemia
0 Views
administrator
07/08/23
Dr Roberts presents the promising results from an early phase trial combining the anti-bcl-2 drug venetoclax with rituximab to eliminate chronic lymphocytic leukaemia (CLL) at a press conference at EHA 2015.
-
Category
Show more
Facebook Comments
No comments found